Limits...
Magnetic nanosystem for cancer therapy using oncocalyxone a, an antitomour secondary metabolite isolated from a Brazilian plant.

Barreto AC, Santiago VR, Freire RM, Mazzetto SE, Denardin JC, Mele G, Cavalcante IM, Ribeiro ME, Ricardo NM, Gonçalves T, Carbone L, Lemos TL, Pessoa OD, Fechine PB - Int J Mol Sci (2013)

Bottom Line: Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties.The MO-20 presented a size of about 30 nm and globular morphology.In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport.

View Article: PubMed Central - PubMed

Affiliation: Advanced Materials Chemistry Group (GQMAT), Analytical and Physical-Chemistry Department, Federal University of Ceará (UFC), Campus do Pici 12100, CEP 60451-970 Fortaleza-CE, Brazil. fechine@ufc.br.

ABSTRACT
This paper describes the investigation and development of a novel magnetic drug delivery nanosystem (labeled as MO-20) for cancer therapy. The drug employed was oncocalyxone A (onco A), which was isolated from Auxemma oncocalyx, an endemic Brazilian plant. It has a series of pharmacological properties: antioxidant, cytotoxic, analgesic, anti-inflammatory, antitumor and antiplatelet. Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties. The components of MO-20 were characterized by XRD, FTIR, TGA, TEM and Magnetization curves. The MO-20 presented a size of about 30 nm and globular morphology. In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport. The results found in this work showed the potential of onco A for future applications of the MO-20 as a new magnetic drug release nanosystem for cancer treatment.

Show MeSH
Weight loss by thermogravimetric analysis (a) Fe3O4; (b) MO-20 and (c) copolymer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3794780&req=5

f6-ijms-14-18269: Weight loss by thermogravimetric analysis (a) Fe3O4; (b) MO-20 and (c) copolymer.

Mentions: To investigate thermal behavior and determine the amount of magnetic nanoparticles present in MO-20, TGA were performed and illustrated in Figure 6. The magnetite amounts from samples can be estimated from the residual mass percentages. Magnetic nanoparticles powder showed practically no weight loss in the temperature range 25 to 800 °C due to their high thermal stability (Figure 6a). On the other hand TGA data for MO-20 nanosystem demonstrated that the first weight loss occurs at about 200 °C (Figure 6b), which is 100 °C lower than for the pure copolymer (Figure 6c). This shift in the temperature might be ascribed to the presence of oleic acid and onco A multilayers in MO-20. In both cases a second degradation starts around 325 °C indicative of a mass loss of 25 and 32 wt% for MO-20 and the copolymer, respectively. As illustrated in Figure 6b the remaining metal nanoparticle (magnetite) content is almost 10 wt% in MO-20, whereas copolymer thermograms showed a complete weight loss over the temperature range 25 to 800 °C. Ilgin et al. [31] studying magnetic composites based on hyaluronic acid hydrogel observed 20% nanoparticle weight content by TGA analysis.


Magnetic nanosystem for cancer therapy using oncocalyxone a, an antitomour secondary metabolite isolated from a Brazilian plant.

Barreto AC, Santiago VR, Freire RM, Mazzetto SE, Denardin JC, Mele G, Cavalcante IM, Ribeiro ME, Ricardo NM, Gonçalves T, Carbone L, Lemos TL, Pessoa OD, Fechine PB - Int J Mol Sci (2013)

Weight loss by thermogravimetric analysis (a) Fe3O4; (b) MO-20 and (c) copolymer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3794780&req=5

f6-ijms-14-18269: Weight loss by thermogravimetric analysis (a) Fe3O4; (b) MO-20 and (c) copolymer.
Mentions: To investigate thermal behavior and determine the amount of magnetic nanoparticles present in MO-20, TGA were performed and illustrated in Figure 6. The magnetite amounts from samples can be estimated from the residual mass percentages. Magnetic nanoparticles powder showed practically no weight loss in the temperature range 25 to 800 °C due to their high thermal stability (Figure 6a). On the other hand TGA data for MO-20 nanosystem demonstrated that the first weight loss occurs at about 200 °C (Figure 6b), which is 100 °C lower than for the pure copolymer (Figure 6c). This shift in the temperature might be ascribed to the presence of oleic acid and onco A multilayers in MO-20. In both cases a second degradation starts around 325 °C indicative of a mass loss of 25 and 32 wt% for MO-20 and the copolymer, respectively. As illustrated in Figure 6b the remaining metal nanoparticle (magnetite) content is almost 10 wt% in MO-20, whereas copolymer thermograms showed a complete weight loss over the temperature range 25 to 800 °C. Ilgin et al. [31] studying magnetic composites based on hyaluronic acid hydrogel observed 20% nanoparticle weight content by TGA analysis.

Bottom Line: Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties.The MO-20 presented a size of about 30 nm and globular morphology.In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport.

View Article: PubMed Central - PubMed

Affiliation: Advanced Materials Chemistry Group (GQMAT), Analytical and Physical-Chemistry Department, Federal University of Ceará (UFC), Campus do Pici 12100, CEP 60451-970 Fortaleza-CE, Brazil. fechine@ufc.br.

ABSTRACT
This paper describes the investigation and development of a novel magnetic drug delivery nanosystem (labeled as MO-20) for cancer therapy. The drug employed was oncocalyxone A (onco A), which was isolated from Auxemma oncocalyx, an endemic Brazilian plant. It has a series of pharmacological properties: antioxidant, cytotoxic, analgesic, anti-inflammatory, antitumor and antiplatelet. Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties. The components of MO-20 were characterized by XRD, FTIR, TGA, TEM and Magnetization curves. The MO-20 presented a size of about 30 nm and globular morphology. In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport. The results found in this work showed the potential of onco A for future applications of the MO-20 as a new magnetic drug release nanosystem for cancer treatment.

Show MeSH